Researchers investigate a novel treatment for Childhood Alzheimer’s
Category: #health  By Saipriya Iyer  Date: 2020-06-25
  • share
  • Twitter
  • Facebook
  • LinkedIn

Researchers investigate a novel treatment for Childhood Alzheimer’s

Researchers at the Lundquist Institute have reportedly collaborated with the Cure Sanfilippo Foundation on a new clinical trial to investigate if repurposing an anti-inflammatory drug could provide relief to children that suffer from Sanfilippo syndrome, also referred as Childhood Alzheimer’s.

With majority of clinical trials currently focused on finding a vaccine for COVID-19, the team at The Lundquist Institute continues its efforts towards developing a treatment for Sanfilippo syndrome as safely and quickly as possible.

For the record, Sanfilippo syndrome, also known as MPS III (mucopolysaccharidosis type III), is a rare genetic disorder that has distressing effect on patient’s nervous system. People affected with this disease lack an enzyme that helps break down large sugar molecules in the body.

According to credible sources, the clinical trial was designed by Drs. Agnes Chen and Lynda Polgreen from The Lundquist Institute in partnership with Dr. Cara O’Neill, Chief Science Officer at Cure Sanfilippo Foundation and Dr. Julie Eisengart, Director, Neurodevelopmental Program in Rare Disease at UNM Medical School.

Reports claim that Dr. Cara O’Neill effectively recognized the potential of new research around the role of inflammation in this disease and how current FDA-approved treatments could ameliorate symptoms in patients. She identified pharmaceutical and clinical partners to utilize this concept in a clinical trial for children suffering from Sanfilippo Syndrome, leading her to The Lundquist Institute.

Elaborating on anticipated developments, the clinical trial is estimated to begin in May whilst involving 20 children with Sanfilippo syndrome. The candidates will be given anakinra, which blocks the activity of a protein called interleukin-1 (IL-1) that leads to joint damage, thereby lowering inflammation.

Repurposing a preexisting drug to treat patients with Sanfilippo syndrome could endow a cost-efficient as well as timely way to enhance the quality of living of children suffering from this fatal disease.

Source Credit: https://www.businesswire.com/news/home/20200624005203/en/Unique-Clinical-Trial-Investigates-New-Treatment-Approach



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Target and Kohl’s to sell beauty products as department stores reel
Target and Kohl’s to sell beauty products as department stores reel
By Saipriya Iyer

Some retailers are speculating that eye shadow palettes, facial scrubs, and lip glosses will likely be the upcoming popular thing that would bring significant customer attention, especially the younger generation, to t...

U.S. FDA approves adjunctive therapy & intravenous use of VIMPAT®
U.S. FDA approves adjunctive therapy & intravenous use of VIMPAT®
By Saipriya Iyer

UCB, a biopharmaceutical company, has recently gained the approval of the U.S. FDA (Food & Drug Administration) for its prescription medicine, VIMPAT®.

VIMPAT

ECA alleges Amazon misused non-public data of retailers to its benefit
ECA alleges Amazon misused non-public data of retailers to its benefit
By Saipriya Iyer

The ECA (European Competition Authorities), in preliminary findings, has reportedly alleged that American e-commerce giant Amazon “systematically relied on non-public business information of independent sellers&r...